Genomic Health (FRA:G7H) Short-Term Debt & Capital Lease Obligation : €4.1 Mil (As of Sep. 2019)

View and export this data going back to . Start your Free Trial

What is Genomic Health Short-Term Debt & Capital Lease Obligation?

Short-Term Debt & Capital Lease Obligation is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt. Genomic Health's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was €4.1 Mil.

Long-Term Debt & Capital Lease Obligation is the debt and capital lease obligation due more than 12 months in the future. Genomic Health's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2019 was €46.1 Mil.

Genomic Health Short-Term Debt & Capital Lease Obligation Historical Data

The historical data trend for Genomic Health's Short-Term Debt & Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genomic Health Short-Term Debt & Capital Lease Obligation Chart

Genomic Health Annual Data

Trend

Dec09

Dec10

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Short-Term Debt & Capital Lease Obligation

Get a 7-Day Free Trial

Genomic Health Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
Short-Term Debt & Capital Lease Obligation	Get a 7-Day Free Trial															-	-	3.98	3.93	4.11

Genomic Health Short-Term Debt & Capital Lease Obligation Calculation

This is the portion of a company's debt and capital lease obligation that need to be paid within the next 12 months. It equals Short-Term Debt plus Short-Term Capital Lease Obligation. This gives investors an idea of how much money the company needs to pay down for the principle of its debt.

In the notes to balance sheet in annual (10-K) or quarterly (10-Q) reports, companies usually break down the details of the debt, their due dates, the interest rates etc.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

Genomic Health Short-Term Debt & Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Genomic Health's Short-Term Debt & Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Genomic Health (FRA:G7H) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Genomic Health Inc (FRA:G7H) » Definitions » Short-Term Debt & Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

N/A

Address

301 Penobscot Drive, Redwood City, CA, USA, 94063

Website

http://www.genomichealth.com

Genomic Health Inc provides genomic-based diagnostic tests that focus on the treatment of early-stage cancer. The firm's Oncotype DX tests analyze the expression levels of genes in tumor tissue samples and provide a numeric score that physicians can use to determine the aggressiveness of breast, colon, or prostate cancer. These test results can guide decisions about the use of chemotherapy, radiation, surgery, or other aggressive treatments. The Oncotype DX breast cancer test generates the majority of the firm's revenue, analyzing 21 genes to determine the optimal treatment for stage I, II, or IIa breast cancer. The majority of Genomic Health's sales occur within the United States.

Genomic Health (FRA:G7H) Headlines

No Headlines